- Home
- HCWB vs KORE Comparison
HCWB vs KORE Comparison
Compare HCWB & KORE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- KORE
- Stock Information
- Founded
- HCWB 2018
- KORE 2003
- Country
- HCWB United States
- KORE United States
- Employees
- HCWB N/A
- KORE N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- KORE Telecommunications Equipment
- Sector
- HCWB Health Care
- KORE Consumer Discretionary
- Exchange
- HCWB Nasdaq
- KORE Nasdaq
- Market Cap
- HCWB 26.6M
- KORE 24.7M
- IPO Year
- HCWB 2021
- KORE N/A
- Fundamental
- Price
- HCWB $0.37
- KORE $2.02
- Analyst Decision
- HCWB
- KORE Buy
- Analyst Count
- HCWB 0
- KORE 2
- Target Price
- HCWB N/A
- KORE $10.00
- AVG Volume (30 Days)
- HCWB 274.4K
- KORE 579.9K
- Earning Date
- HCWB 11-14-2024
- KORE 11-19-2024
- Dividend Yield
- HCWB N/A
- KORE N/A
- EPS Growth
- HCWB N/A
- KORE N/A
- EPS
- HCWB N/A
- KORE N/A
- Revenue
- HCWB $3,495,990.00
- KORE $285,229,000.00
- Revenue This Year
- HCWB $229.19
- KORE $3.89
- Revenue Next Year
- HCWB N/A
- KORE $5.35
- P/E Ratio
- HCWB N/A
- KORE N/A
- Revenue Growth
- HCWB 22.27
- KORE 7.01
- 52 Week Low
- HCWB $0.28
- KORE $1.10
- 52 Week High
- HCWB $2.52
- KORE $5.45
- Technical
- Relative Strength Index (RSI)
- HCWB 43.55
- KORE 51.10
- Support Level
- HCWB $0.33
- KORE $1.77
- Resistance Level
- HCWB $0.38
- KORE $4.88
- Average True Range (ATR)
- HCWB 0.05
- KORE 0.52
- MACD
- HCWB -0.00
- KORE -0.04
- Stochastic Oscillator
- HCWB 25.97
- KORE 11.18
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates a majority of its revenue from the United States and the rest from other countries.